Company intelligence / Profile preview
RxBio
Johnson City, Tennessee, United Statesrxbio.com ↗
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
01
Overview
RxBio's lead compound Rx100 has demonstrated significant survival benefits in GI-ARS and HEM-ARS animal models when administered up to 24 hours post-radiation exposure; nearing completion of non-clinical toxicology studies for clinical trials[1][3][4].
- Therapeutic areas
- HematologyRare DiseasesGastroenterology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
National Institute of Allergy and Infectious Disease (NIAID)Biomedical Advanced Research and Development Authority (BARDA)U.S. Army / Department of Defense
Beyond the preview
Go deeper on RxBio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RxBio.